Restoration of daptomycin sensitivity with adjunctive cefazolin is associated with C-terminal MprF mutations in MRSA bacteremia isolates
Open Access
- 3 June 2026
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (6) , e0154725
Abstract
Daptomycin (DAP) or vancomycin (VAN) resistance can result in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia treatment failure. Clinical trials have not yielded a clear approach to MRSA combination therapy. Furthermore, there is not a protocol approved by the Clinical Laboratory Standards Institute (CLSI) for testing most possible antibiotic combinations, and methodology used in basic research laboratories for combination testing presents significant hurdles for implementation in clinical laboratories. In response to these challenges, we developed a high-throughput antibiotic combination testing assay to measure the minimum antibiotic concentration(s) required to reach 99% growth inhibition (IC99) and used it to identify antibiotics that can be paired with DAP to restore the DAP susceptibility of DAP-resistant (DAP-R) MRSA. The IC99 recapitulated time-kill curve results and were consistent with results of single drug MIC measurements performed under CLSI conditions. Using this assay, we found that cefazolin (CFZ) restored DAP susceptibility for DAP-R MRSA with L826F and Q692E mutations in the C-terminal region of the synthase domain of the multiple peptide resistance factor MprF. CFZ also improved VAN susceptibility when used in combination with VAN against these isolates. We established the association between the L826F MprF mutation and CFZ improvement in DAP (and VAN) susceptibility using an MprF deletion strain and transcomplementation with WT MprF compared with L826F MprF. This study highlights the IC99 assay’s potential for identifying antibiotic treatment for DAP-R MRSA bacteremia and suggests a probable link between MprF synthase domain mutations and CFZ’s ability to improve or restore DAP or VAN susceptibility.Keywords
Funding Information
- National Institutes of Health (K12TR004384)
This publication has 63 references indexed in Scilit:
- Effect of in vitro synergy and additivity of vancomycin or daptomycin plus an antistaphylococcal β-lactam for methicillin-resistant Staphylococcus aureus bacteraemia on mortality: preplanned analysis from CAMERA2Clinical Microbiology and Infection, 2026
- Daptomycin: Mechanism of action, mechanisms of resistance, synthesis and structure-activity relationships2024
- Antibiotic Development: Lessons from the Past and Future OpportunitiesPharmaceutical Research, 2024
- The Golden Grapes of Wrath – Staphylococcus aureus Bacteremia: A Clinical ReviewThe American Journal of Medicine, 2022
- Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysisClinical Microbiology and Infection, 2022
- Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort AnalysisInfectious Diseases and Therapy, 2020
- Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA BacteremiaJAMA, 2020
- Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolatesJournal of Microbiology, 2017
- Observation of “Seesaw Effect” with Vancomycin, Teicoplanin, Daptomycin and Ceftaroline in 150 Unique MRSA StrainsInfectious Diseases and Therapy, 2014
- Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE)European Journal of Clinical Microbiology & Infectious Diseases, 2009